NCT00165256 Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast Status COMPLETED Phase PHASE2
NCT00165230 Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors Status COMPLETED Phase PHASE2
NCT00165204 Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy Status COMPLETED Phase PHASE2
NCT00165152 Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing Status COMPLETED Phase NA
NCT00153985 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Status COMPLETED Phase PHASE2
NCT00153933 Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT00153920 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma Status COMPLETED Phase PHASE2
NCT00148707 Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT00148668 Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer Status COMPLETED Phase PHASE2
NCT00146614 Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation Status COMPLETED Phase PHASE2
NCT00146601 Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Status COMPLETED Phase PHASE2
NCT00146588 Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer Status COMPLETED Phase NA
NCT00146562 Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer Status COMPLETED Phase PHASE2
NCT00146536 Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy Status COMPLETED Phase N/A
NCT00142480 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Status COMPLETED Phase PHASE2
NCT00142467 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma Status COMPLETED Phase PHASE2
NCT00142428 Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Status COMPLETED Phase PHASE2